Noregen® (CTR-107) is a synthetic protein modeled after norrin, a naturally occurring protein that guides retinal formation in fetal development. It targets the progressive loss of the tiny capillary vessels and promotes their organized re-growth. The ultimate promise is to reverse vision loss in diseases affecting retinal and choroidal blood vessels.
Norrin performs these functions in the body:
We’ve found that Noregen® (CTR-107) functions similarly. In mouse models it:
Noregen® (CTR-107) is a unique, novel regenerative, retinal therapeutic that is derived from an endogenous human protein and is backed by solid in vitro and in vivo science. Noregen® (CTR-107) addresses an urgent unmet need in patients with inherited or acquired retinal diseases. There is also exciting potential for expansion of Noregen’s® (CTR-107) therapeutic range beyond retinal diseases.
On January 27, 2022 the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for Noregen® (CTR-107), the first potential regenerative therapy for the treatment of Familial Exudative Vitreoretinopathy (FEVR) associated vision loss. Read the press release here.
For more information about our collaborative development work with Dr. Kenneth Mitton at Oakland University, click here.
For more information regarding our Oakland University partners, click here.
For more information about Noregen® (CTR-107) or our science email us at [email protected]
As a company dedicated to pursuit of regenerative medicine approaches for sensory-related diseases, Caeregen Therapeutics applies leading-edge science and technologies to the discovery and development of novel therapies to repair, restore, and protect diseased or damaged sensory and neurologic structures.